Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial | Journal of the American College of Cardiology
Overview of ODYSSEY trials included in this analysis (randomized... | Download Scientific Diagram
PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time? - Minneapolis Heart Institute Foundation
OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition - PACE-CME
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial - ScienceDirect
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events | NEJM
Scientific and Clinical Advances in Dyslipidemia: Focus on PCSK9 (Transcript)
What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials | SpringerLink
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial - Journal of Clinical Lipidology
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials | Scientific Reports
Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies - Journal of Clinical Lipidology
![PDF] Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b12de40ec702d75a66ce5e40c62d4071f8709f65/3-Figure1-1.png "PDF] Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. | Semantic Scholar")
PDF] Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. | Semantic Scholar
Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial - Atherosclerosis
Current Dyslipidemia Management Guidelines Residual Risk. - ppt download
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials - International Journal of Cardiology
Current Evidence and Future Directions of PCSK9 Inhibition | USC Journal Current Evidence and Future Directions of PSCK9 Inhibition
2018/03 – IR Call – Odyssey Outcomes
Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON - Journal of Cardiology
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) - Journal of Clinical Lipidology
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial - ScienceDirect
What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials | SpringerLink
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial - ScienceDirect
Overview of the Phase 3 ODYSSEY trials included in the analysis and... | Download Scientific Diagram
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based ...
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses - Journal of Clinical Lipidology
